Targeting the Noradrenergic System in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis of Prazosin Trials
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Post-traumatic stress disorder (PTSD) is a chronic psychiatric disorder that may develop after exposure to a life-threatening trauma. As veterans and armed forces may deal with diverse health problems compared with civilians, they have a greater risk for psychiatric disorders, including PTSD, than civilians, even if the disorder may be also frequent in the general population. PTSD is associated with significant comorbidity, especially with mood disorders and substance abuse. Moreover, the suicide risk is higher in PTSD patients than in the general population. Selective Serotonin Reuptake Inhibitors (SSRIs), atypical antipsychotics and benzodiazepines are commonly employed in the management of PTSD, but often these treatments fail or are discontinued due to adverse effects. It has been demonstrated that high noradrenergic activity may be associated with hyperarousal, trauma nightmares and sleep disturbances in PTSD subjects, probably through the stimulation of α -1 adrenergic receptors in the brain prefrontal cortex. The α -1 adrenoreceptor antagonist prazosin decreases noradrenaline effects at brain α-1 adrenoreceptors and may be a promising agent in the treatment of PTSD, as some studies have found it effective and well tolerated. Therefore, the present review is aimed to examine the role of noradrenergic system in the pathophysiology of PTSD. Moreover, we conducted a systematic review to evaluate the effectiveness and tolerability of prazosin in PTSD patients. Meta-analysis was used to combine data from multiple studies and better estimate the effect of prazosin on specific outcomes. We found prazosin to be significantly more efficacious than placebo in reducing distressing dreams in PTSD patients, even though our results should be interpreted with caution due to the small number of studies included in our quantitative synthesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder
Southwick, S. M., Bremner, J. D., Rasmusson, A., Morgan, C. A., Arnsten, A., & Charney, D. S. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00219-x · Cited by 573
Cited by
Citrome, L., Ota, A., Nagamizu, K., Perry, P., Weiller, E., & Baker, R. A. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000123 · Cited by 74
“The α1 antagonist prazosin, for example, has been shown to improve agitation associated with Alzheimer’s disease (Wang et al., 2009) and hyperarousal/sleep disturbances associated with posttraumatic stress syndrome (De Berardis et al., 2015).”
BackgroundPrazosin for treatment of post-traumatic stress disorder: a systematic review and meta-analysis
Reist, C., Streja, E., Tang, C. C., Shapiro, B., Mintz, J., & Hollifield, M. (2021) · CNS Spectrums · doi:10.1017/s1092852920001121 · Cited by 56
Cardoner, N., Andero, R., Cano, M., Marin-Blasco, I., Porta-Casteràs, D., Serra-Blasco, M., Via, E., Vicent-Gil, M., & Portella, M. J. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230703091435 · Cited by 45
“…among them, which confer different subtypes within each diagnostic category, especially MDD, possibly casting doubt on such common neurobiological underpinnings [13-15], multidimensional models derived from comprehensive descriptions of micro to macro factors may represent an opportunity [16].”
BackgroundZiaee, A., Nejat, H., Amarghan, H. A., & Fariborzi, E. (2021) · European Journal of Translational Myology · doi:10.4081/ejtm.2022.10271 · Cited by 13
Metadata
- Authors
- Berardis, D., Marini, S., Serroni, N., Iasevoli, F., Tomasetti, C., Bartolomeis, A., Mazza, M., Tempesta, D., Valchera, A., Fornaro, M., Pompili, M., Sepede, G., Vellante, F., Orsolini, L., Martinotti, G., & Giannantonio, M.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2015-09-30
- Volume
- 16
- Issue
- 10
- Pages
- 1094-1106
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W2132336597
- Cited by
- 112
- References
- 1
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the Noradrenergic System in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis of Prazosin Trials. https://app.cochat.ai/papers/10.2174/1389450116666150506114108
- The paper
- Berardis, D., Marini, S., Serroni, N., Iasevoli, F., Tomasetti, C., Bartolomeis, A., Mazza, M., Tempesta, D., Valchera, A., Fornaro, M., Pompili, M., Sepede, G., Vellante, F., Orsolini, L., Martinotti, G., & Giannantonio, M. (2015). Targeting the Noradrenergic System in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis of Prazosin Trials. Current Drug Targets. https://doi.org/10.2174/1389450116666150506114108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.